Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage

Ke, Zhi‐Bin; Chen, Jia-Yin; You, Qi; Sun, Jiang-Bo; Xue, Yu-Ting; Ye, Xiaojian; Chen, Shao‐Hao; Xue, Xue-Yi; Sun, Xiong‐Lin; Chen, Dong‐Ning; Wei, Yong; Zheng, Qing‐Shui; Chen, Shaoming; Xu, Ning

doi:10.1007/s00432-022-04438-8

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although previous studies have explored predictive factors for the occurrence time of CRPC, a unified predictive factor has not yet been established. [28][29][30] For example, for patients receiving intermittent endocrine therapy, due to PSA fluctuations, especially for prostate cancer patients undergoing radical surgery or radiation therapy, the longer the interval between PSA rises, the longer it will take for the patient to develop CRPC.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance

Li,

Cui,

Zhao

et al. 2024

IJGM

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance

Li,

Cui,

Zhao

et al. 2024

IJGM

View full text Add to dashboard Cite

Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview

Caracciolo,

Castello,

Castellani

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Objectives: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has gained a primary role in prostate cancer (PCa) imaging, overcoming conventional imaging and prostate-specific antigen (PSA) serum levels, and has recently emerged as a promising technique for monitoring therapy response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with novel hormonal therapy, taxanes, and radioligand therapy (RLT). In this review, we aim to provide an overview of the most relevant aspects under study and future prospects related to the prognostic role of PSMA PET/CT in mCRPC. Methods: A systematic literature search was performed in the following databases: MEDLINE, PubMed, and EMBASE databases. The study focused exclusively on English-language studies, excluding papers not pertinent to the topic. Results: PSMA PET imaging offers a higher sensitivity and specificity than conventional imaging and provides accurate staging and efficient diagnosis of distant metastases. The data presented herein highlight the usefulness of PET in risk stratification, with a prognostic potential that can have a significant impact on clinical practice. Several prospective trials are ongoing and will shortly provide more evidence supporting the prognostic potential of PET PSMA data in this clinical scenario. Conclusions: Current evidence proves the prognostic role of PSMA PET/CT in different settings, with raising relevance also in the context of mCRPC.

show abstract

Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage

Cited by 2 publications

References 37 publications

Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance

Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance

Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview

Contact Info

Product

Resources

About